Maxillary Nerve Blocks in Children - An MRI Study of the Suprazygomatic Approach
Launched by OSLO UNIVERSITY HOSPITAL · Mar 20, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a method called the suprazygomatic maxillary nerve block (SMNB) in young children who are having surgery for a condition known as cleft palate. The purpose of the trial is to see how effectively a local anesthetic spreads to numb the area around the maxillary nerve, which is important for managing pain after surgery. To do this, researchers will use a special imaging technique called MRI to visualize where the anesthetic goes after it is injected.
To participate in this trial, children need to be between 10 to 24 months old and scheduled for cleft palate surgery. Their overall health should be good, meaning they fall into a category that indicates they are not seriously ill. Parents or guardians must provide written consent for their child to join the study. Participants will receive the nerve block as part of their pain management during the surgery, and the study will help doctors learn more about the best ways to manage pain in children after such procedures.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Paediatric patients scheduled for cleft palate (CP) surgery with SMNB as part of their perioperative pain treatment
- • American Society of Anesthesiologists physical status 1 - 2
- • Age 10 to 24 months
- • Given informed written consent by legal guardian
- Exclusion Criteria:
- • American Society of Anesthesiologists physical status \> 2
- • Patients with cranial deformation
- • Patients with concomitant medical treatments or medical conditions interfering with peripheral nerve block treatment
- • Patients with concomitant medical treatments or medical conditions interfering with MRI
- • Patients that are allergic to bupivacaine or other local anaesthetic agents.
About Oslo University Hospital
Oslo University Hospital is a leading academic medical center in Norway, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes the development of new therapies and treatment strategies. With a multidisciplinary approach, Oslo University Hospital collaborates with various stakeholders, including researchers, healthcare professionals, and industry partners, to enhance clinical outcomes and contribute to the global medical community. Its dedication to ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and respect for participant welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oslo, , Norway
Patients applied
Trial Officials
Axel Sauter, MD PhD
Principal Investigator
Oslo University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials